Amarin (NASDAQ:AMRN) Sets New 12-Month Low - What's Next?
Amarin Co. plc (NASDAQ:AMRN) reached a new 52-week low of $0.44 during trading, closing at $0.46. Analysts have issued a "sell" rating, with a market cap of $3.74 billion and a negative earnings per share of ($2.40). The company reported revenue of $62.31 million, exceeding estimates. Institutional investors have increased their stakes, with 22.25% of shares owned by hedge funds. Amarin specializes in therapeutics for cardiovascular diseases, notably VASCEPA for reducing triglyceride levels.
Amarin Co. plc (NASDAQ:AMRN - Get Free Report) reached a new 52-week low during trading on Friday . The stock traded as low as $0.44 and last traded at $9.11, with a volume of 1319852 shares. The stock had previously closed at $0.46.
Analysts Set New Price Targets
- 3 Biotech Stocks Gaining Momentum
Separately, StockNews.com began coverage on shares of Amarin in a report on Tuesday. They issued a "sell" rating on the stock.
View Our Latest Research Report on AMRN
Amarin Stock Performance
- Are Ocugen or Amarin Good Penny Stocks to Buy?
The firm has a 50-day moving average price of $0.50 and a two-hundred day moving average price of $0.53. The firm has a market cap of $3.74 billion, a price-to-earnings ratio of -98.89 and a beta of 1.38.
Amarin (NASDAQ:AMRN - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by ($1.20). The company had revenue of $62.31 million for the quarter, compared to analyst estimates of $32.37 million. Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. Research analysts anticipate that Amarin Co. plc will post -0.15 earnings per share for the current year.
Institutional Trading of Amarin
- Does Amarin Deserve a Spot in Your Portfolio after Earnings ?
Several institutional investors and hedge funds have recently made changes to their positions in the company. Arkfeld Wealth Strategies L.L.C. increased its position in Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 20,000 shares during the period. LCM Capital Management Inc raised its position in Amarin by 3.1% in the 4th quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company's stock valued at $407,000 after purchasing an additional 25,100 shares during the last quarter. LPL Financial LLC grew its position in Amarin by 26.0% during the 4th quarter. LPL Financial LLC now owns 153,020 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 31,555 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Amarin by 3.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,340,920 shares of the biopharmaceutical company's stock valued at $650,000 after purchasing an additional 39,452 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of Amarin in the fourth quarter valued at about $36,000. 22.25% of the stock is owned by hedge funds and other institutional investors.
Amarin Company Profile
(Get Free Report)Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Recommended Stories
- Five stocks we like better than Amarin
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Rocket Lab Stock: Weathering the Storm, Time for a Comeback?
- 5 discounted opportunities for dividend growth investors
- Snowflake Boosts Growth by Doubling Down on AI
- How to Use Stock Screeners to Find Stocks
- IAMGOLD Stock Climbs as Turnaround Story Gains Traction
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Amarin Right Now?
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
